{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-014819","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.253270+00:00","generated_at":"2026-05-15T07:49:39.197886+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cocrystal Pharma receives FDA Fast Track designation for norovirus antiviral CDI-988","bullets":["FDA granted Fast Track designation for oral, direct-acting protease inhibitor CDI-988 for norovirus.","CDI-988 is first oral antiviral candidate for both treatment and prophylaxis of norovirus infection.","Phase 1b double-blind challenge study (NCT07198139) ongoing at Emory University in up to 40 adults.","Norovirus causes ~685M global infections/year with ~$60B worldwide economic impact.","Fast Track enables rolling NDA review and potential Priority Review; no financial terms disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-014819","json":"https://secwatch.observer/filing/0001493152-26-014819.json","markdown":"https://secwatch.observer/filing/0001493152-26-014819.md","text":"https://secwatch.observer/filing/0001493152-26-014819.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226014819/0001493152-26-014819-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226014819/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:49:39.197886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}